Back to results
US 2010/0305179 A1Published application
Oral sustained-release tablet
AssigneesKyorin Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd.
InventorsRyouichi HOSHINO, Katashi Nakashima, Kazuo Kazama
Life of this patent
Estimating the term…
Abstract
(Object) An oral sustained-release tablet is provided, which does not cause initial rapid increases in the bloodlevels of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide (KRP-197) and can maintain constant the blood levels. (Solving means) An oral sustained-release tablet comprises a pharmaceutical composition and a gel-forming material, the pharmaceutical composition containing KRP-197 as an active ingredient.
Claims9
1-5. (canceled)
A method of producing an oral sustained-release tablet, said method comprising:
- spraying a solution comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide on to an excipient in a fluidised state to prepare granules comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide;
- mixing the granules with a gel-forming material to prepare a granular composition;
- and
- compressing the granular composition to form the tablet.
1 more element
Dependencies are inferred from the claim text.